ArticleJAC-antimicrobial resistance2021
CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales.
Article in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Rapid Molecular Diagnostics for MDR Nosocomial Infections in ICUs: Integration with Prevention, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2025Review
- Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.The Lancet. Infectious diseases · 2024Article
- Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.The Journal of antimicrobial chemotherapy · 2024Article
- Article
- Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin.JAC-antimicrobial resistance · 2023Article
- Evaluation of Piperacillin-Tazobactam Testing againstJournal of clinical microbiology · 2023Article
- Trends of β-Lactamase Occurrence AmongOpen forum infectious diseases · 2023Article
- Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae.Journal of clinical microbiology · 2022Article
- Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial Challenge in Acute Care Surgery.Antibiotics (Basel, Switzerland) · 2022Review
- Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- Impact of Generic Entry on Hospital Antimicrobial Use: A Retrospective Quasi-Experimental Interrupted Time Series Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.JAC-antimicrobial resistance · 2021Review
- Navigating treatment approaches for presumed ESBL-producing infections.JAC-antimicrobial resistance · 2021Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxone-resistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include β-lactam/β-lactamase inhibitor combinations, temocillin, cephamycins and some non-β-lactam drugs. The most controversial is piperacillin/tazobactam; the results of the MERINO trial are challenged because the isolates of patients with worse outcomes were frequently not susceptible to piperacillin/tazobactam when studied by reference methods, and also because the drug was not administered in extended infusion. Other potential options are briefly discussed. We conclude that carbapenems are not necessary for all patients with infections caused by ceftriaxone-resistant Enterobacterales.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.